Maxim Group Reiterates “Buy” Rating for Capricor Therapeutics (CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a note issued to investors on Wednesday. They presently have a $4.00 price objective on the biotechnology company’s stock. Maxim Group’s price target indicates a potential upside of 354.55% from the company’s previous close.

The analysts wrote, “Capricor reported 3Q18 with a net loss of ($4.1M) and ended the period with $10.4M in cash on the balance sheet, runway into 2Q18. We do expect that the company will need to raise capital in early 2019, prior to reaching data for the HOPE-2 study, which is expected in 2020.””

Several other analysts also recently weighed in on CAPR. Zacks Investment Research downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. TheStreet downgraded shares of Capricor Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, October 15th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $4.83.

NASDAQ:CAPR opened at $0.88 on Wednesday. Capricor Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.48.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.90 million. Capricor Therapeutics had a negative return on equity of 146.11% and a net margin of 24.75%. On average, analysts expect that Capricor Therapeutics will post -0.53 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Article: Analyzing a company’s cash flow statement

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply